These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17694446)

  • 1. Anticalins as alternative binding proteins for therapeutic use.
    Skerra A
    Curr Opin Mol Ther; 2007 Aug; 9(4):336-44. PubMed ID: 17694446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities.
    Skerra A
    FEBS J; 2008 Jun; 275(11):2677-83. PubMed ID: 18435758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticalins: the lipocalin family as a novel protein scaffold for the development of next-generation immunotherapies.
    Hohlbaum AM; Skerra A
    Expert Rev Clin Immunol; 2007 Jul; 3(4):491-501. PubMed ID: 20477155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticalins as an alternative to antibody technology.
    Schlehuber S; Skerra A
    Expert Opin Biol Ther; 2005 Nov; 5(11):1453-62. PubMed ID: 16255649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticalins: exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins.
    Richter A; Eggenstein E; Skerra A
    FEBS Lett; 2014 Jan; 588(2):213-8. PubMed ID: 24239535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combinatorial design of an Anticalin directed against the extra-domain b for the specific targeting of oncofetal fibronectin.
    Gebauer M; Schiefner A; Matschiner G; Skerra A
    J Mol Biol; 2013 Feb; 425(4):780-802. PubMed ID: 23238252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticalins small engineered binding proteins based on the lipocalin scaffold.
    Gebauer M; Skerra A
    Methods Enzymol; 2012; 503():157-88. PubMed ID: 22230569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'Anticalins': a new class of engineered ligand-binding proteins with antibody-like properties.
    Skerra A
    J Biotechnol; 2001 Jun; 74(4):257-75. PubMed ID: 11526907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticalins in drug development.
    Schlehuber S; Skerra A
    BioDrugs; 2005; 19(5):279-88. PubMed ID: 16207069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction of an artificial receptor protein ("anticalin") based on the human apolipoprotein D.
    Vogt M; Skerra A
    Chembiochem; 2004 Feb; 5(2):191-9. PubMed ID: 14760740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duocalins: engineered ligand-binding proteins with dual specificity derived from the lipocalin fold.
    Schlehuber S; Skerra A
    Biol Chem; 2001 Sep; 382(9):1335-42. PubMed ID: 11688717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The menagerie of human lipocalins: a natural protein scaffold for molecular recognition of physiological compounds.
    Schiefner A; Skerra A
    Acc Chem Res; 2015 Apr; 48(4):976-85. PubMed ID: 25756749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineered protein scaffolds as next-generation antibody therapeutics.
    Gebauer M; Skerra A
    Curr Opin Chem Biol; 2009 Jun; 13(3):245-55. PubMed ID: 19501012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipocalins in drug discovery: from natural ligand-binding proteins to "anticalins".
    Schlehuber S; Skerra A
    Drug Discov Today; 2005 Jan; 10(1):23-33. PubMed ID: 15676296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-affinity Anticalins with aggregation-blocking activity directed against the Alzheimer β-amyloid peptide.
    Rauth S; Hinz D; Börger M; Uhrig M; Mayhaus M; Riemenschneider M; Skerra A
    Biochem J; 2016 Jun; 473(11):1563-78. PubMed ID: 27029347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-guided engineering of Anticalins with improved binding behavior and biochemical characteristics for application in radio-immuno imaging and/or therapy.
    Eggenstein E; Eichinger A; Kim HJ; Skerra A
    J Struct Biol; 2014 Feb; 185(2):203-14. PubMed ID: 23542582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural plasticity in the loop region of engineered lipocalins with novel ligand specificities, so-called Anticalins.
    Achatz S; Jarasch A; Skerra A
    J Struct Biol X; 2022; 6():100054. PubMed ID: 34988429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies.
    Schönfeld D; Matschiner G; Chatwell L; Trentmann S; Gille H; Hülsmeyer M; Brown N; Kaye PM; Schlehuber S; Hohlbaum AM; Skerra A
    Proc Natl Acad Sci U S A; 2009 May; 106(20):8198-203. PubMed ID: 19416843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative non-antibody scaffolds for molecular recognition.
    Skerra A
    Curr Opin Biotechnol; 2007 Aug; 18(4):295-304. PubMed ID: 17643280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticalins directed against the fibronectin extra domain B as diagnostic tracers for glioblastomas.
    Albrecht V; Richter A; Pfeiffer S; Gebauer M; Lindner S; Gieser E; Schüller U; Schichor C; Gildehaus FJ; Bartenstein P; Tonn JC; Skerra A; Glass R
    Int J Cancer; 2016 Mar; 138(5):1269-80. PubMed ID: 26421425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.